Archer Materials reports a major technical advance in quantum computing with electrical readout of carbon-based qubits, alongside progress on its Biochip medical diagnostic prototype, setting the stage for commercialisation in 2026.
- Electrical detection of quantum states in carbon qubits achieved
- Reproducible device performance and wafer-scale synthesis validated
- Biochip development advances with dual graphene and silicon platforms
- Strategic partnerships with Emergence Quantum, CSIRO, and IMEC expanded
- Net loss narrowed to $3 million with strong $10.3 million cash position
Quantum Breakthrough: Electrical Readout of Carbon Qubits
Archer Materials has marked a significant milestone in the quantum technology race by successfully achieving electrical readout of quantum states in its proprietary carbon-based qubit materials. This breakthrough, demonstrated through on-chip electrical detection of magnetic resonance and single-electron transistor devices, sidesteps the need for complex optical systems traditionally used in diamond-based quantum computing. The result not only reduces technical risk but also opens a scalable and semiconductor-compatible pathway for future quantum devices.
Further validation came from reproducible device performance across wafer-scale synthesis, with electron spin lifetimes exceeding 0.4 microseconds at room temperature. These achievements underscore Archer’s potential to integrate quantum computing components with existing CMOS semiconductor technology, a critical factor for practical deployment.
Biochip Progress: Dual-Platform Strategy Targets Clinical Prototype
On the medical diagnostics front, Archer advanced its Biochip technology designed for potassium sensing in human blood, a key marker for chronic kidney disease. The company is pursuing a dual-platform approach, developing both graphene-based and silicon-based devices. Collaboration with IMEC has yielded promising results for the silicon Biochip, demonstrating clinical-grade accuracy and faster readout times, which could accelerate scalable manufacturing.
Archer aims to deliver a functional Biochip prototype in 2026, with preparations underway for regulatory approval pathways and clinical trials. This dual approach strategically mitigates supply chain risks and positions the company for quicker commercialisation.
Strategic Partnerships and Corporate Developments
To accelerate its technology roadmap, Archer expanded partnerships with Emergence Quantum, focusing on next-generation quantum materials, and CSIRO, targeting quantum machine learning applications such as fraud detection in financial transactions. These collaborations broaden Archer’s commercial horizons beyond hardware into software and data-intensive domains.
Corporate governance also evolved with the appointment of Andrew Just, an experienced health industry executive, to the Board as a Non-Executive Director. This move aims to bolster the Biochip’s development and commercialisation efforts.
Financial Snapshot: Improved Losses and Strong Cash Position
Financially, Archer narrowed its net loss to $2.99 million for the half-year ended December 2025, down from $4.42 million the previous year, reflecting disciplined expenditure on research and development. The company maintains a robust cash position of $10.3 million, supporting ongoing R&D and commercialisation activities without corporate debt.
While no dividends were declared, Archer’s investment in intellectual property and prototype development signals a focus on long-term value creation. The company’s share-based payment plans also aim to retain key talent as it transitions from research to commercialisation phases.
Looking Ahead: Prototype Demonstrations and Commercial Partnerships
Archer is poised to demonstrate targeted qubit functionality and Biochip prototypes during 2026, milestones that will be critical for attracting global commercial partners and advancing regulatory approvals. The company’s ability to translate these technical achievements into market-ready products will be closely watched by investors and industry observers alike.
Bottom Line?
Archer’s quantum and Biochip advances set a promising stage for 2026, but execution risks and funding needs remain key watchpoints.
Questions in the middle?
- How soon can Archer demonstrate a fully operational qubit device suitable for commercial use?
- What regulatory hurdles remain for the Biochip’s clinical trial and market approval?
- How will Archer manage funding and partnerships to sustain its R&D momentum beyond 2026?